Status migrainosus: a potential adverse reaction to Comirnaty (BNT162b2, BioNtech/Pfizer) COVID-19 vaccine—a case report
| العنوان: | Status migrainosus: a potential adverse reaction to Comirnaty (BNT162b2, BioNtech/Pfizer) COVID-19 vaccine—a case report |
|---|---|
| المؤلفون: | Stefano Consoli, Giacomo Evangelista, Marco Onofrj, Laura Bonanni, Fedele Dono, D. Travaglini, Maria D'Apolito |
| المصدر: | Neurological Sciences |
| بيانات النشر: | Springer International Publishing, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Adult, medicine.medical_specialty, Pediatrics, Neurology, COVID-19 Vaccines, Aura, Status migrainosus, Migraine Disorders, Dermatology, medicine.disease_cause, Pandemic, Case report, medicine, Humans, Comirnaty BNT162b2, Adverse effect, BNT162 Vaccine, Coronavirus, Vaccines, Synthetic, business.industry, SARS-CoV-2, COVID-19, General Medicine, medicine.disease, Vaccination, Psychiatry and Mental health, Migraine, Migraine without aura, Liposomes, Nanoparticles, Female, Neurology (clinical), Neurosurgery, mRNA Vaccines, business |
| الوصف: | Background Coronavirus disease-19 (COVID-19) due to acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is the largest emergency that humanity had to be dealing with in the last century. During the last months, different types of vaccines have been designed to contain the ongoing SARS-CoV-2 pandemic, with successful results in many countries. Comirnaty (Pfizer/BioNtech) COVID-19 vaccine is a lipid nanoparticle-formulated, nucleoside mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2. Although vaccines have an undeniable efficacy, they can also present several neurological side effects, including headache. According to ICHD-3 Classification, status migrainosus (SMg) is described as a debilitating migraine attack lasting for more than 72 h. Symptoms of SMg can be very severe, preventing the normal daily activities of the individual. Case presentation In the present report, we describe a case of SMg that lasted 11 days, time correlated with the second dose of COVID-19 vaccine (Pfizer/Comirnaty) in a 37-year-old woman with a history of migraine without aura. Conclusions In patients with a history of migraine, COVID-19 vaccination could lead to a worsening of headache and, in rare cases, to the development of a SMg. This may be related to the inflammatory response that occurs after vaccination. Supplementary Information The online version contains supplementary material available at 10.1007/s10072-021-05741-x. |
| اللغة: | English |
| تدمد: | 1590-3478 1590-1874 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60555ee60bf462c29842b5e5eed31fdcTest http://europepmc.org/articles/PMC8607053Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....60555ee60bf462c29842b5e5eed31fdc |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15903478 15901874 |
|---|